The Prevention and Treatment of Obesity

Wirth, Alfred; Wabitsch, Martin; Hauner, Hans

doi:10.3238/arztebl.2014.0705

Cited by 103 publications

(108 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The scope of conventional treatment was obtained from the SOS study [27]. These data are in line with results of systematic literature reviews and meta-analyses [12,53,54,55], where conventionally treated patients received the unstandardized nonsurgical treatment for obesity, ranging from sophisticated lifestyle intervention and behavior modification to no treatment whatsoever. No cost was assumed for the conventional treatment.…”

Section: Methodssupporting

confidence: 53%

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Lucchese

Borisenko²,

Mantovani

et al. 2017

Obes Facts

View full text Add to dashboard Cite

Objective: To evaluate the cost-effectiveness of bariatric surgery in Italy from a third-party payer perspective over a medium-term (10 years) and a long-term (lifetime) horizon. Methods: A state-transition Markov model was developed, in which patients may experience surgery, post-surgery complications, diabetes mellitus type 2, cardiovascular diseases or die. Transition probabilities, costs, and utilities were obtained from the Italian and international literature. Three types of surgeries were considered: gastric bypass, sleeve gastrectomy, and adjustable gastric banding. A base-case analysis was performed for the population, the characteristics of which were obtained from surgery candidates in Italy. Results: In the base-case analysis, over 10 years, bariatric surgery led to cost increment of EUR 2,661 and generated additional 1.1 quality-adjusted life years (QALYs). Over a lifetime, surgery led to savings of EUR 8,649, additional 0.5 life years and 3.2 QALYs. Bariatric surgery was cost-effective at 10 years with an incremental cost-effectiveness ratio of EUR 2,412/QALY and dominant over conservative management over a lifetime. Conclusion: In a comprehensive decision analytic model, a current mix of surgical methods for bariatric surgery was cost-effective at 10 years and cost-saving over the lifetime of the Italian patient cohort considered in this analysis.

show abstract

Section: Methodssupporting

confidence: 53%

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Lucchese

Borisenko²,

Mantovani

et al. 2017

Obes Facts

View full text Add to dashboard Cite

show abstract

“…The literature has shown that weight loss decreases MetS markers, thus reducing risk factors for CVD, T2DM, some types of cancer, and skeletal abnormalities, which positively affects individuals' quality of life (22) . However, the literature also suggests that interventions advocating behavioral and lifestyle changes (i.e., diet and exercise) and drug therapy have little success and low adherence over time for obese class II and III patients with comorbidities (9) .…”

Section: Discussionmentioning

confidence: 99%

Impact of Roux-en-Y Gastric Bypass Surgery (Rygb) on Metabolic Syndrome Components and on the Use of Associated Drugs in Obese Patients

Junges

Cavalheiro²,

Fam³

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -The prevalence of obesity and metabolic syndrome is increasing worldwide and both behavior modification and drug therapy have low adherence. Gastric bypass has shown effective results in both reducing weight and improving comorbidities. Objective -To evaluate the impact of Roux-en-Y Gastric Bypass Surgery (RYGB) on both metabolic syndrome components and the use of associated drugs in obese patients. Methods -Historical cohort of patients subjected to Roux-en-Y Gastric Bypass Surgery (RYGB) between January 2007 and March 2014 in a private clinic. The sample consisted of 273 obese class II and III individuals, 86.4% of whom were female, with age ≥20 years, followed up for 2 months after surgery. Sociodemographic, anthropometric, biochemical, clinical, and drug-use data were collected from patients' medical records. Results -Significant differences were found in weight, body mass index and waist circumference, after 60 postoperative days. Components for metabolic syndrome diagnosis (hypertension P=0.001; hyperglycemia P<0.001; hypertriglyceridemia P=0.006) were reduced after 60 days of postoperative, with the exception HDL-c (P=0.083). There was a significant reduction in the use of antihypertensive (P<0.001), hypoglycemic (P=0.013), lipid lowering (P<0.001), and antiobesity (P=0.010) drugs and increased use of gastroprotective drugs, vitamins, and minerals (P<0.001) after 60 postoperative days. ConclusionPatients subjected to Roux-en-Y Gastric Bypass Surgery exhibited both weight loss and significant improvement not only in metabolic syndrome components (except for HDL-c) but in the use of drugs associated with obesity and metabolic syndrome. HEADINGS -Metabolic syndrome X. Obesity. Gastric bypass. Drug utilization.

show abstract

“…Weight reduction programs are a part of many standard obesity treatment and prevention guidelines such as the German Obesity Society guidelines, concerning success and quality [85]. The aim of these weight loss strategies is not weight loss alone but also an improvement of cardiovascular and metabolic risk factors, following a healthy lifestyle (physical activity and diet) and raising the quality of life.…”

Section: Goal-setting: Realistic Weight Lossmentioning

confidence: 99%

“…There is agreement that long-term therapeutic lifestyle changes (TLC) such as dietary behavior reformations and increasing daily physical activity, are the cornerstones in the prevention and management of obesity and its related health risk factors and are often combined with cognitive behavior modification techniques [10,85]. Furthermore, the use of meal replacements has been accepted as an effective therapeutic strategy for weight loss, particularly in the beginning of an intervention [4,5,26,83,85].…”

mentioning

confidence: 99%

See 1 more Smart Citation

The effect of a soy-yoghurt-honey product on excess weight and related health risk factors - A review

Koohkan¹,

McCarthy²,

Berg³

2017

JNHFS

View full text Add to dashboard Cite

achieve this goal, supervised programs can be applied over a period of at least 6 months delivered by an interdisciplinary team of physicians, psychologists and group behavior consultants and nutritionists. This approach produces healthy modifications in diet and exercise for an individual's every day practice [10].Even if such a program is insufficient to prove the long-term success, the significant findings in obese adults confirms that using modified lifestyle interventions are at least comparable with the results of pharmacological interventions after 12-months [66]. Nevertheless, it is discouraging knowing the level of success in weight loss programs while only a very small number of obese patients can be motivated to participate in a lifestyle intervention program [25].There is agreement that long-term therapeutic lifestyle changes (TLC) such as dietary behavior reformations and increasing daily physical activity, are the cornerstones in the prevention and management of obesity and its related health risk factors and are often combined with cognitive behavior modification techniques [10,85]. Furthermore, the use of meal replacements has been accepted as an effective therapeutic strategy for weight loss, particularly in the beginning of an intervention [4,5,26,83,85].Dietary approaches can achieve as much weight loss in obese outpatients as has been reported for the most successful drug treatments, but compliance with the prescribed diet can be poor unless the dietary recommendations are simple to follow [73]. Moreover, weight loss interventions utilizing a meal replacement together with dietary counselling and increased physical activity have led to substantial and significant favorable reductions in anthropometric measurements and metabolic risk factors while preserving skeletal muscle mass [7,8]. T h e following review will specially focus on the efficiency of a clinically proven meal replacement product which is commercially available as a soy-yoghurt-honey formula (SYHF; Almased®) against overweight, obesity and its related health risks. AbstractThere is an agreement that long-term Therapeutic Lifestyle Changes (TLC) such as dietary behavior reformations and increasing daily physical activity, are the cornerstones in the prevention and management of obesity and its related health risk factors. Furthermore, the use of meal replacement diet has been accepted as an effective therapeutic strategy for a successful weight loss, particularly in the beginning of an intervention. The following review will specially focus on the efficiency of a clinically approved meal replacement product which is commercially available as a Soy-Yoghurt-Honey Formula (SYHF) which can be used to prevent, treat or manage overweight, obesity and its related health risks. The mentioned positive effects come not only by formula's low glycemic index as well as low caloric characteristics, but by its biologically active components such as soy isoflavones and soy and milk biological active peptides as well as antioxidants, enzymes and o...

show abstract

The Prevention and Treatment of Obesity

Abstract: There is good scientific evidence for effective measures for the prevention and treatment of obesity.

Cited by 103 publications

References 42 publications

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Impact of Roux-en-Y Gastric Bypass Surgery (Rygb) on Metabolic Syndrome Components and on the Use of Associated Drugs in Obese Patients

The effect of a soy-yoghurt-honey product on excess weight and related health risk factors - A review

Contact Info

Product

Resources

About